References

clinmed

Клиническая медицина

Clinical Medicine (Russian Journal)

0023-21492412-1339

ООО «Медицинское информационное агентство»

10.30629/0023-2149-2023-101-7-8-353-360

clinmed-590

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Эпигенетические сигналы при сердечной недостаточности: новые возможности для ранней диагностики и эффективной терапии

Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy

https://orcid.org/0000-0003-4973-039X

Айтбаев

А. К.

Aitbaev

K. A.

Айтбаев Кубаныч Авенович — д-р мед. наук, профессор, зав. лабораторией патологической физиологии и иммунологии; член правления Общества специалистов по хронической болезни почек

720040, Бишкек

720040, Bishkek

kaitbaev@yahoo.com

https://orcid.org/0000-0001-8513-9279

Муркамилов

И. Т.

Murkamilov

I. T.

Муркамилов Илхом Торобекович — д-р мед. наук, доцент кафедры факультетской терапии; доцент кафедры терапии № 2 медицинского факультета; председатель правления Общества специалистов по хронической болезни почек

720040, Бишкек; 720000, Бишкек

720020, Bishkek; 720000, Bishkek

https://orcid.org/0000-0002-2682-4417

Фомин

В. В.

Fomin

V. V.

Фомин Виктор Викторович — д-р мед. наук, профессор, член-корр. РАН, зав. кафедрой факультетской терапии № 1; проректор по инновационной и клинической деятельности

119991, Москва

119991, Moscow

https://orcid.org/0000-0003-3007-8127

Кудайбергенова

И. О.

Kudaibergenova

I. O.

Кудайбергенова Индира Орозобаевна — д-р мед.наук, профессор, ректор

720020, Bishkek

https://orcid.org/0000-0003-0632-6653

Юсупов

Ф. А.

Yusupov

F. A.

Юсупов Фуркат Абдулахатович — д-р мед. наук, профессор, зав. кафедрой неврологии, нейрохирургии и психиатрии медицинского факультета; член правления Общества специалистов по хронической болезни почек Кыргызстана, главный невролог Южного региона

723500, Ош

723500, Osh

https://orcid.org/0000-0003-2323-5702

Айдаров

З. А.

Aidarov

Z. A.

Айдаров Зиябидин Абдирайимович — д-р мед. наук, профессор, зав. кафедрой общественного здоровья и здравоохранения, декан факультета «Лечебное дело»; член правления Общества специалистов по хронической болезни почек Кыргызстана

720020, Бишкек

720020, Bishkek

Научно-исследовательский институт молекулярной биологии и медициныКыргызстанScientifi c and Research Institute of Molecular Biology and MedicineKyrgyzstan

Кыргызская государственная медицинская академия им. И.К. Ахунбаева; ГОУ ВПО «Кыргызско-Российский славянский университет имени первого Президента Российской Федерации Б.Н. Ельцина»КыргызстанKyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz-Russian Slavic University named after the First President of the Russian Federation B.N. YeltsinKyrgyzstan

Институт клинической медицины им. Н.В. Склифосовского; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)Russian Federation

Кыргызская государственная медицинская академия им. И.К. АхунбаеваКыргызстанKyrgyz State Medical Academy named after I.K. AkhunbaevKyrgyzstan

Ошский государственный университетКыргызстанOsh State UniversityKyrgyzstan

2023

22092023

1017-8353360

2023

Айтбаев А.К., Муркамилов И.Т., Фомин В.В., Кудайбергенова И.О., Юсупов Ф.А., Айдаров З.А.

Aitbaev K.A., Murkamilov I.T., Fomin V.V., Kudaibergenova I.O., Yusupov F.A., Aidarov Z.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.clinmedjournal.com/jour/article/view/590

Сердечная недостаточность (СН) представляет собой тяжелый клинический синдром, связанный со значительной заболеваемостью и смертностью. Согласно механизмам развития СН подразделяется на две основные клинические формы: сердечную недостаточность с низкой фракцией выброса (СНнФВ) и сердечную недостаточность с сохраненной фракцией выброса (СНсФВ). Если для СНнФВ были разработаны эффективные и специфические методы лечения, благодаря которым распространенность этой формы СН снизилась за последние годы, то в отношении пациентов с СНсФВ прогноз остается неблагоприятным, а эффективных методов лечения пока не существует. В связи с этим идентификация новых молекулярных мишеней и терапевтических подходов представляется важной задачей современной медицины. Данные, полученные в этом направлении, выявили ключевое участие эпигенетических сигналов в регуляции программ транскрипции, лежащих в основе развития СНсФВ, что способствовало разработке селективных эпигенетических препаратов, способных удалять транскрипционные изменения и тем самым задерживать или предотвращать прогрессирование СНсФВ. Дальнейшее тщательное исследование индивидуального эпигенетического ландшафта может предоставить в будущем возможности для разработки персонализированных эпигенетических биомаркеров и методов лечения СНсФВ. Цель настоящего обзора — рассмотреть роль эпигенетического процессинга, а также его диагностические и терапевтические возможности при СНсФВ.

Heart failure (HF) is a severe clinical syndrome associated with signifi cant morbidity and mortality. According to the mechanisms of HF development, it is divided into two main clinical forms: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). While eff ective and specifi c treatment methods have been developed for HFrEF, leading to a decrease in the prevalence of this form of HF in recent years, the prognosis for patients with HFpEF remains unfavourable, and eff ective treatment methods do not yet exist. Therefore, the identifi cation of new molecular targets and therapeutic approaches is considered an important task of modern medicine. Data obtained in this fi eld have revealed the key involvement of epigenetic signals in the regulation of transcriptional programs underlying the development of HFpEF, which has contributed to the development of selective epigenetic drugs capable of reversing transcriptional changes and thus delaying or preventing the progression of HFpEF. Further thorough investigation of individual epigenetic landscapes may provide opportunities in the future for the development of personalized epigenetic biomarkers and treatment methods for HFpEF. The aim of this review is to consider the role of epigenetic processing, as well as its diagnostic and therapeutic possibilities in HFpEF.

биомаркерыэпигенетикасердечная недостаточность с сохраненной фракцией выбросаперсонализированная медицина

biomarkersepigeneticsheart failure with preserved ejection fractionpersonalized medicine

References1

Paulus W.J. Culprit mechanism(s) for exercise intolerance in heart failure with normal ejection fraction. J. Am. Coll. Cardiol. 2010;56:864–866. DOI: 10.1016/j.jacc.2010.04.041

Dunlay S.M., Roger V.L., Redfi eld M.M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2017;14:591– 602. DOI: 10.1038/nrcardio.2017.65

Dunlay S.M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2017;14:591–602. DOI: 10.1038/nrcardio.2017.65

Leggat J., Bidault G., Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? Clin. Sci. 2021;135:2265– 2283. DOI: 10.1042/CS20210127

Leggat J., Bidault G., Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? Clin. Sci. 2021;135:2265–2283. DOI: 10.1042/CS20210127

Wenzl F.A., Ambrosini S., Mohammed S. et al. Infl ammation in metabolic cardiomyopathy. Front Cardiovasc. Med. 2021;8:742178. DOI: 10.3389/fcvm.2021.742178

Wenzl F.A., Ambrosini S., Mohammed S. et al. Inflammation in metabolic cardiomyopathy. Front Cardiovasc. Med. 2021;8:742178. DOI: 10.3389/fcvm.2021.742178

Jackson A.M., Rorth R., Liu J. et al. Diabetes and prediabetes in patients with heart failure and preserved ejection fraction. Eur. J. Heart Fail. 2021;DOI: 10.1002/ejhf.2403

Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. 2011;32:670–679. DOI: 10.1093/eurheartj/ehq426

Borlaug B.A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2014;11:507–515. DOI: 10.1038/nrcardio.2014.83

Owan T.E., Hodge D.O., Herges R.M. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006;355:251–259. DOI: 10.1056/NEJMoa052256

Seferovic P.M., Vardas P., Jankowska E.A. et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. Eur. J. Heart Fail. 2021;23:906–914. DOI: 10.1002/ejhf.2143

Savarese G., Lund L.H. Global public health burden of heart failure. Card. Fail. Rev. 2017;3:7–11. DOI: 10.15420/cfr.2016:25:2

Costantino S., Libby P., Kishore R. et al. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. Eur. Heart J. 2018;39:4150–4158. DOI: 10.1093/eurheartj/ehx568

Aguilera O., Fernandez A.F., Munoz A., Fraga M.F. Epigenetics and environment: a complex relationship. J. Appl. Physiol. 2010;109:243–251. DOI: 10.1152/japplphysiol.00068.2010

Jawaid A., Jehle K.L., Mansuy I.M. Impact of parental exposure on off spring health in humans. Trends Genet. 2021;37:373–388. DOI: 10.1016/j.tig.2020.10.006

Costantino S., Mohammed S.A., Ambrosini S., Paneni F. Epigenetic processing in cardiometabolic disease. Atherosclerosis. 2019;281:150–158. DOI: 10.1016/j.atherosclerosis.2018.09.029

El-Osta A. Redox mediating epigenetic changes confer metabolic memories. Circ. Res. 2012;111:262–264. DOI: 10.1161/CIRCRESAHA.112.274936

Hamdani N., Costantino S., Mugge A. et al. Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. Eur. Heart J. 2021;42:1940–1958. DOI: 10.1093/eurheartj/ehab197

Soler-Botija C., Galvez-Monton C., Bayes-Genis A. Epigenetic biomarkers in cardiovascular diseases. Front Genet. 2019;10:950. DOI: 10.3389/fgene.2019.00950

Berdasco M., Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat. Rev. Genet. 2019;20:109–127. DOI: 10.1038/s41576-018-0074-2

Arora I., Tollefsbol T.O. Computational methods and next-generation sequencing approaches to analyze epigenetics data: profi ling of methods and applications. Methods. 2021;187:92–103. DOI: 10.1016/j.ymeth.2020.09.008

Arora I., Tollefsbol T.O. Computational methods and next-generation sequencing approaches to analyze epigenetics data: profiling of methods and applications. Methods. 2021;187:92–103. DOI: 10.1016/j.ymeth.2020.09.008

Schiano C., Benincasa G., Franzese M. et al. Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases. Pharmacol. Ther. 2020;210:107514. DOI: 10.1016/j.pharmthera.2020.107514

Bain C.R., Ziemann M., Kaspi A. et al. DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure. ESC Heart Fail. 2020;7:2468–2478. DOI: 10.1002/ehf2.12810

Meder B., Haas J., Sedaghat-Hamedani F. et al. Epigenome-wide association study identifi es cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation. 2017;136:1528–1544. DOI: 10.1161/CIRCULATIONAHA.117.027355

Meder B., Haas J., Sedaghat-Hamedani F. et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation. 2017;136:1528–1544. DOI: 10.1161/CIRCULATIONAHA.117.027355

Glezeva N., Moran B., Collier P. et al. Targeted DNA methylation profi ling of human cardiac tissue reveals novel epigenetic traits and gene deregulation across diff erent heart failure patient subtypes. Circ. Heart Fail. 2019;12:e005765. DOI: 10.1161/CIRCHEARTFAILURE.118.005765

Glezeva N., Moran B., Collier P. et al. Targeted DNA methylation profiling of human cardiac tissue reveals novel epigenetic traits and gene deregulation across different heart failure patient subtypes. Circ. Heart Fail. 2019;12:e005765. DOI: 10.1161/CIRCHEARTFAILURE.118.005765

Sano S., Wang Y., Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. Circ. J. 2018;83:2–11. DOI: 10.1253/circj.CJ-18-0871

Dorsheimer L., Assmus B., Rasper T. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25–33. DOI: 10.1001/jamacardio.2018.3965

Eaton C., Raffi eld L.M., Bick A. et al. Abstract 11: prospective association of Tet2 mediated clonal hematoopoiesis and heart failure and its subtypes in postmenopausal women. Circulation. 2020;141:(1):A11–A111.

Eaton C., Raffield L.M., Bick A. et al. Abstract 11: prospective association of Tet2 mediated clonal hematoopoiesis and heart failure and its subtypes in postmenopausal women. Circulation. 2020;141:(1):A11–A111.

Sano S., Wang Y., Yura Y. et al. JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl. Sci. 2019;4:684–697. DOI: 10.1016/j.jacbts.2019.05.013

Donekal S., Venkatesh B.A., Liu Y.C. et al. Interstitial fi brosis, left ventricular remodeling, and myocardial mechanical behavior in a population-based multiethnic cohort: the Multi-Ethnic Study of Atherosclerosis (MESA) study. Circ. Cardiovasc. Imaging. 2014;7:292– 302. DOI: 10.1161/CIRCIMAGING.113.001073

Donekal S., Venkatesh B.A., Liu Y.C. et al. Interstitial fibrosis, left ventricular remodeling, and myocardial mechanical behavior in a population-based multiethnic cohort: the Multi-Ethnic Study of Atherosclerosis (MESA) study. Circ. Cardiovasc. Imaging. 2014;7:292–302. DOI: 10.1161/CIRCIMAGING.113.001073

Duprez D.A., Gross M.D., Kizer J.R. et al. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Heart Assoc. 2018;7:e007885. DOI: 10.1161/JAHA.117.007885

Gabel S.A., Walker V.R., London R.E. et al. Estrogen receptor beta mediates gender diff erences in ischemia/reperfusion injury. J. Mol. Cell Cardiol. 2005;38:289–297. DOI: 10.1016/j.yjmcc.2004.11.013

Gabel S.A., Walker V.R., London R.E. et al. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J. Mol. Cell Cardiol. 2005;38:289–297. DOI: 10.1016/j.yjmcc.2004.11.013

Schiattarella G.G., Rodolico D., Hill J.A. Metabolic infl ammation in heart failure with preserved ejection fraction. Cardiovasc. Res. 2021;117:423–434. DOI: 10.1093/cvr/cvaa217

Schiattarella G.G., Rodolico D., Hill J.A. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc. Res. 2021;117:423–434. DOI: 10.1093/cvr/cvaa217

Cetin M., Kocaman S.A., Durakoglugil M.E. et al. Effect of epicardial adipose tissue on diastolic functions and left atrial dimension in untreated hypertensive patients with normal systolic function. J. Cardiol. 2013;61:359–364. DOI: 10.1016/j.jjcc.2012.12.015

Nerlekar N., Muthalaly R.G., Wong N. et al. Association of volumetric epicardial adipose tissue quantification and cardiac structure and function. J. Am. Heart. Assoc. 2018;7:e009975. DOI: 10.1161/JAHA.118.009975

Oikonomou E.K., Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat. Rev. Cardiol. 2019;16:83–99. DOI: 10.1038/s41569-018-0097-6

Oikonomou E.K., Antoniades C. The role of adipose tissue in cardio-vascular health and disease. Nat. Rev. Cardiol. 2019;16:83–99. DOI: 10.1038/s41569-018-0097-6

Crujeiras A.B., Diaz-Lagares A., Moreno-Navarrete J.M. et al. Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects. Transl. Res. 2016;178:13–24. DOI: 10.1016/j.trsl.2016.07.002

Kaneda R., Takada S., Yamashita Y. et al. Genome-wide histone methylation profi le for heart failure. Genes Cells. 2009;14:69–77. DOI: 10.1111/j.1365-2443.2008.01252.x

Kaneda R., Takada S., Yamashita Y. et al. Genome-wide histone methylation profile for heart failure. Genes Cells. 2009;14:69–77. DOI: 10.1111/j.1365-2443.2008.01252.x

Wei J., Joshi S., Speransky S. et al. Reversal of pathological cardiac hypertrophy via the MEF2-coregulator interface. JCI Insight. 2017;2:e91068. DOI: 10.1172/jci.insight.91068

Gilsbach R., Schwaderer M., Preissl S. et al. Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo. Nat. Commun. 2018;9:391. DOI: 10.1038/s41467-017-02762-z

Rahier J.F., Druez A., Faugeras L. et al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin. Epigenetics. 2017;9:53. DOI: 10.1186/s13148-017-0351-5

Watson C.J., Gupta S.K., O’Connell E. et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur. J. Heart Fail. 2015;17:405–415. DOI: 10.1002/ejhf.244

Chen F., Yang J., Li Y., Wang H. Circulating microRNAs as novel biomarkers for heart failure. Hellenic J. Cardiol. 2018;59:209–214. DOI: 10.1016/j.hjc.2017.10.002

Rech M., Barandiaran Aizpurua A., van Empel V. et al. Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. Cardiovasc. Res. 2018;114:782–793. DOI: 10.1093/cvr/cvy049

Costantino S., Paneni F., Cosentino F. Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. Curr. Pharm. Biotechnol. 2015;16:531–543. DOI: 10.2174/138920101606150407113644

Fraineau S., Palii C.G., Allan D.S., Brand M. Epigenetic regulation of endothelial-cell-mediated vascular repair. FEBS J. 2015;282:1605– 1629. DOI: 10.1111/febs.13183

Fraineau S., Palii C.G., Allan D.S., Brand M. Epigenetic regulation of endothelial-cell-mediated vascular repair. FEBS J. 2015;282:1605–1629. DOI: 10.1111/febs.13183

Yekehtaz H., Farokhnia M., Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J. Tehran. Heart Cent. 2013;8:169–176.

Lyle M.A., Alabdaljabar M.S., Han Y.S., Brozovich F.V. The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes. Heliyon. 2020;6:e03129. DOI: 10.1016/j.heliyon.2019.e03129

Severs N.J. Gap junction remodeling in heart failure. J. Card. Fail. 2002;8:S293–299. DOI: 10.1054/jcaf.2002.129255.

Ooi J.Y., Tuano N.K., Rafehi H. et al. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Epigenetics. 2015;10:418–430. DOI: 10.1080/15592294.2015.1024406

Lyu X., Hu M., Peng J. et al. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis. Ther. Adv. Chronic Dis. 2019;10:2040622319862697. DOI: 10.1177/2040622319862697 50. Napoli C., Bontempo P., Palmieri V.et al. Epigenetic therapies for heart failure: current insights and future potential. Vasc. Health Risk Manag. 2021;17:247–254. DOI: 10.2147/VHRM.S287082

Lyu X., Hu M., Peng J. et al. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis. Ther. Adv. Chronic Dis. 2019;10:2040622319862697. DOI: 10.1177/2040622319862697

Kao Y-H., Cheng C-C., Chen Y-C. et al. Hydralazine-induced promoter de-methylation enhances sarcoplasmic reticulum Ca2+- ATPase and calcium homeostasis in cardiac myocytes. Lab. Investig. 2011;91:1291–1297. DOI: 10.1038/labinvest.2011.92

Napoli C., Bontempo P., Palmieri V.et al. Epigenetic therapies for heart failure: current insights and future potential. Vasc. Health Risk Manag. 2021;17:247–254. DOI: 10.2147/VHRM.S287082

Lee C., Kim B.G., Kim J.H. et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. Int. Immunopharmacol. 2017;51:47–56. DOI: 10.1016/j.intimp.2017.07.023

Kao Y-H., Cheng C-C., Chen Y-C. et al. Hydralazine-induced promoter de-methylation enhances sarcoplasmic reticulum Ca2+ - ATPase and calcium homeostasis in cardiac myocytes. Lab. Investig. 2011;91:1291–1297. DOI: 10.1038/labinvest.2011.92

Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NFκB in the heart. Circ. Res. 2011;108:1122–1132. DOI: 10.1161/CIRCRESAHA.110.226928

Gillette T.G., Hill J.A. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ. Res. 2015;116:1245–1253. DOI: 10.1161/CIRCRESAHA.116.303630

Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NF-κB in the heart. Circ. Res. 2011;108:1122–1132. DOI: 10.1161/CIRCRESAHA.110.226928

Khurana I., Maxwell S., Royce S. et al. SAHA attenuates Takotsubo-like myocardial injury by targeting an epigenetic Ac/Dc axis. Signal Transduct. Target Ther. 2021;6:159. DOI: 10.1038/s41392-021-00546-y

Gillette T.G., Hill J.A. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ. Res. 2015;116:1245–1253. DOI: 10.1161/CIRCRESAHA.116.303630

Duan Q., McMahon S., Anand P. et al. BET bromodomain inhibition suppresses innate infl ammatory and profi brotic transcriptional networks in heart failure. Sci. Transl. Med. 2017;9:eaah5084. DOI: 10.1126/scitranslmed.aah5084

Jahagirdar R., Zhang H., Azhar S. et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE defi cient mice. Atherosclerosis. 2014;236:91–100. DOI: 10.1016/j.atherosclerosis.2014.06.008

Duan Q., McMahon S., Anand P. et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci. Transl. Med. 2017;9:eaah5084. DOI: 10.1126/scitranslmed.aah5084

Tsujikawa L.M., Fu L., Das S. et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin. Epigenet. 2019;11:102. DOI: 10.1186/s13148-019-0696-z

Jahagirdar R., Zhang H., Azhar S. et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236:91–100. DOI: 10.1016/j.atherosclerosis.2014.06.008

Mohammed S.A., Albiero M., Ambrosini S. et al. The BET protein inhibitor apabetalone rescues diabetes-induced impairment of angiogenic response by epigenetic regulation of thrombospondin-1. Antioxid. Redox Signal. 2021. DOI: 10.1089/ars.2021.0127. [Online ahead of print].

Ray K.K., Nicholls S.J., Buhr K.A. et al. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. JAMA. 2020;323:1565–1573. DOI: 10.1001/jama.2020.3308

Mohammed S.A., Albiero M., Ambrosini S. et al. The BET protein inhibitor apabetalone rescues diabetes-induced impairment of an-giogenic response by epigenetic regulation of thrombospondin-1. Antioxid. Redox Signal. 2021. DOI: 10.1089/ars.2021.0127. [Online ahead of print].

Landmesser U., Poller W., Tsimikas S. et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Eur. Heart J. 2020;41:3884–3899. DOI: 10.1093/eurheartj/ehaa229

Batkai S., Genschel C., Viereck J. et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur. Heart J. 2021;42:192–201. DOI: 10.1093/eurheartj/ehaa791

Taubel J., Hauke W., Rump S. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a fi rst-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 2021;42:178–188. DOI: 10.1093/eurheartj/ehaa898

Ly A., Ishiguro L., Kim D. et al. Maternal folic acid supplementation modulates DNA methylation and gene expression in the rat offspring in a gestation period-dependent and organ-specifi c manner. J. Nutr. Biochem. 2016;33:103–110. DOI: 10.1016/j.jnutbio.2016.03.018

Taubel J., Hauke W., Rump S. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-hu-man Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 2021;42:178–188. DOI: 10.1093/eurheartj/ehaa898

Nur S.M, Rath S., Ahmad V. et al. Nutritive vitamins as epidrugs. Crit. Rev. Food Sci. Nutr. 2021;61:1–13. DOI: 10.1080/10408398.2020.1712674

Ly A., Ishiguro L., Kim D. et al. Maternal folic acid supplementation modulates DNA methylation and gene expression in the rat offspring in a gestation period-dependent and organ-specific manner. J. Nutr. Biochem. 2016;33:103–110. DOI: 10.1016/j.jnutbio.2016.03.018

Zhang L., Ji H., Huang Y. et al. Association of BAX hypermethylation with coronary heart disease is specifi c to individuals aged over 70. Medicine. 2019;98:e14130. DOI: 10.1097/MD.0000000000014130

Nur S.M, Rath S., Ahmad V. et al. Nutritive vitamins as epidrugs. Crit. Rev. Food Sci. Nutr. 2021;61:1–13. DOI: 10.1080/10408398.2020.1712674

Jones S.P., Greer J.J., van Haperen R. et al. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. USA. 2003;100:4891–4896. DOI: 10.1073/pnas.0837428100

Zhang L., Ji H., Huang Y. et al. Association of BAX hypermethylation with coronary heart disease is specific to individuals aged over Medicine. 2019;98:e14130. DOI: 10.1097/MD.0000000000014130

D’Amario D., Migliaro S., Borovac J.A. et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol. 2019;10:1347. DOI: 10.3389/fphys.2019.01347

Trum M., Wagner S., Maier L.S., Mustroph J. CaMKII and GLUT1 in heart failure and the role of gliflozins. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165729. DOI: 10.1016/j.bbadis.2020.165729

D’Amario D., Migliaro S., Borovac J.A. et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol. 2019;10:1347. DOI: 10.3389/fphys.2019.01347

Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230. DOI: 10.1016/S0140-6736(08)61239-8

Trum M., Wagner S., Maier L.S., Mustroph J. CaMKII and GLUT1 in heart failure and the role of gliflozins. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165729. DOI: 10.1016/j.bbadis.2020.165729

Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007;357:2248– 2261. DOI: 10.1056/NEJMoa0706201

Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ. Res. 2006;99:692–705. DOI: 10.1161/01.RES.0000243586.99701

Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007;357:2248–2261. DOI: 10.1056/NEJMoa0706201

Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ. Res. 2006;99:692–705. DOI: 10.1161/01.RES.0000243586.99701

The authors declare that there are no conflicts of interest present.